Condition: HIV Infections · Sponsor: ViiV Healthcare
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Bakersfield, California, United States | Recruiting |
| GSK Investigational Site | Palm Springs, California, United States | Recruiting |
| GSK Investigational Site | West Hollywood, California, United States | Recruiting |
| GSK Investigational Site | Aurora, Colorado, United States | Recruiting |
| GSK Investigational Site | New Haven, Connecticut, United States | Recruiting |
| GSK Investigational Site | Ft. Pierce, Florida, United States | Recruiting |
| GSK Investigational Site | Hollywood, Florida, United States | Recruiting |
| GSK Investigational Site | Miami, Florida, United States | Recruiting |
| GSK Investigational Site | Miami Gardens, Florida, United States | Recruiting |
| GSK Investigational Site | Oakland Park, Florida, United States | Recruiting |
| GSK Investigational Site | Orlando, Florida, United States | Recruiting |
| GSK Investigational Site | Orlando, Florida, United States | Recruiting |
+ 111 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07202546